Paul Fonteyne

Paul Fonteyne is the retired Chairman and of Boehringer-Ingelheim USA. He was with Boehringer-Ingelheim for 15 years in leadership roles both in the US and globally. Since November of 2011, he was President and CEO of Boehringer-Ingelheim USA, and subsequently its Chairman (retired 1/1/19). During this time, he led teams that grew BI’s sales and earnings several fold in the USA and participated in acquisitions and divestitures that led to a significantly greater focus of BI’s portfolio of companies in the US in two main segments of Animal Health and Human Pharmaceuticals. He served as President of its Human Pharmaceutical business during a critical period of consolidation of the customer landscape, and important launches for Boehringer-Ingelheim. He served as President of the Animal Health Business in the US during the critical period of integration following the acquisition of Merial. During his 30+ years in the pharmaceutical industry Paul also held commercial leadership roles at Merck and Co. Inc. for 9 years, and Abbott Laboratories for 8 years.

He has served on the board of PhRMA, chaired the National Pharmaceutical Council, Served as Chair of an American cancer Society initiative for New England (CEOs against Cancer), and is on the board of a specialty pharmaceutical company: AMAG, as well as several clinical stage biotechnology companies including Gelesis, DalCor (Chairman), Apellis, and ResTorbio inc. (Chair of compensation Committee), and a device company, Ypsomed AG (Switzerland). In addition, Paul serves as an Executive in Residence to Canaan Partners, a Venture Capital Fund dedicated to Health Care and Technology early stage venture investing. He advises several companies in the Canaan Portfolio.

Paul holds dual citizenship in the USA and Belgium. He holds a MS in Chemical Engineering from the University of Brussels and an MBA for Carnegie Mellon University. He resides in Westport CT with his wife Nathalie. They have three grown children Jaclyn, Louise and Luke; who are all gainfully employed.